Board of Directors

Our Board consists of nine Directors, including four executive Directors, two non-executive Directors and three independent non-executive Directors. The following table provides certain information about our Directors:

NamePositionRoles and responsibilities
Mr. LOU Jing (婁競)

Chairman, president, executive Director and chief executive officer

Strategic development and planning, overall operational management and major decision making of our Group

Mr. TAN Bo (譚擘)

Chief financial officer, executive Director and executive vice president

Overseeing the financial activities and the daily operation of the business development of our Group

Ms. SU Dongmei (蘇冬梅)

Executive Director and senior vice president

Strategic direction and leadership of research and development of our Group

Mr. HUANG Bin (黃斌)

Executive Director and vice president

In charge of administrative management of our Group and the operations management of our subsidiaries and joint ventures

Mr. LIU Dong (劉東)

Non-executive Director

Provide professional opinion and judgment to the Board

Mr. WANG Steven Dasong Non-executive Director Provide professional opinion and judgment to the Board
Mr. PU Tianruo (濮天若)

Independent non-executive Director

Provide professional opinion and judgment to the Board

Dr. David Ross PARKINSON

Independent non-executive Director

Provide professional opinion and judgment to the Board

Mr. MA Jun (馬駿) Independent non-executive Director Provide professional opinion and judgment to the Board

Profiles

Mr. LOU Jing (婁競) was appointed as a Director of our Company on September 5, 2006 and was redesignated as an executive Director of our Company on November 27, 2014. He was appointed as the chairman of the Board on April 1, 2012. Dr. Lou is also our chief executive officer and president. He is responsible for the strategic development and planning, overall operational management and major decision making of our Group. He joined Shenyang Sunshine as a director of research and development in September 1995.

Dr. Lou has been highly active in pharmaceutical research and has made substantial contribution to our research and development of pharmaceutical products. Dr. Lou was the leading scientist and principal investigator in our successful development of EPIAO and TPIAO. He co-invented a “preparation process for recombinant human thrombopoietin” and a “method for improving the stability of polypeptides in human bodies and its application” in 2000 and 2001, respectively. He has published in a number of academic journals on microbiology and medicinal biotechnology. His research has been recognized with various awards. In 2006, he was awarded the “Shenyang Science and Technology Progress Award” (瀋陽市科學技術進步一等獎) for his research on recombinant human thrombopoietin. In 2007, he was awarded the “Liaoning Province Scientific and Technological Achievements Prize” (遼寧省科技成果轉化三等獎) for his contribution to the industrialization of production of recombinant human thrombopoietin. Dr. Lou was also selected as a member of “The Recruitment Program of Global Experts”, which is also known as the “Thousand Talents Program (千人計劃)”, in March 2013.

Dr. Lou obtained a Medical Doctor degree (M.D.) in clinical medicine from Shanghai Second Military Medical University (上海第二軍醫大學) in July 1985. He conducted post-doctoral research at the National Institutes of Health of the United States after obtaining a Ph.D. degree in molecular and cell biology from Fordham University in February 1994. He also obtained an Executive Master of Business Administration from China Europe International Business School (中歐國際工商學院) in September 2008.

Mr. TAN Bo (譚擘) was appointed as a Director of our Company on May 29, 2013 and was redesignated as an executive Director of our Company on November 27, 2014. Mr. Tan is also our chief financial officer and executive vice president. He is responsible for overseeing the financial activities and the daily operation of the business development of our Group. Mr. Tan joined Shenyang Sunshine as the chief financial officer and vice president in February 2009.

Mr. Tan has extensive experience within the financial and pharmaceutical industries, and has worked in private equity, equity research and commercial sectors. He served as executive director and a member of the investment committee of Bohai Industrial Investment Fund Management Company (渤海產業投資基金管理公司) (“Bohai Fund”), a private equity fund in China, from April 2007 to September 2008. Before that, he served as a vice president in the equity research division of Lehman Brothers Asia Limited from March 2006 to March 2007. He worked as a senior analyst at Macquarie Securities Asia in Hong Kong from October 2004 to February 2006.

Mr. Tan obtained a Bachelor’s degree in Economics from Renmin University of China (中國人民大學) in July 1994, a Master’s degree in Economics from the University of Connecticut in December 1996 and a Master of International Management from Thunderbird School of Global Management in August 1998.

Ms. SU Dongmei (蘇冬梅) was appointed as a Director of our Company on June 11, 2012 and was redesignated as an executive Director of our Company on November 27, 2014. Ms. Su is also our senior vice president. She is responsible for strategic direction and leadership of research and development of our Group. Ms. Su joined Shenyang Sunshine as a scientist of the research and development department in January 1993, and served as a director of the research and development department from 1997 to 2006. She subsequently served as chief technology officer responsible for research and development and manufacturing process engineering of Shenyang Sunshine from 2006 to 2008. Ms. Su was promoted to vice president of Shenyang Sunshine in April 2008. Ms. Su served as a director of Shenyang Sunshine from August 2007 to June 2013. Ms. Su is the named co-inventor of four of our patents.

Ms. Su obtained a Bachelor’s degree in Biochemistry from Jilin University (吉林大學) in July 1992 and a Master’s and Doctorate degree in Microbiology and Pharmacology from Shenyang Pharmaceutical University (瀋陽藥科大學) in June 2001 and July 2010, respectively. She has published in a number of academic journals on microbiology and medicinal biotechnology.

Mr. HUANG Bin (黃斌) was first appointed as a Director of our Company on September 5, 2006 and ceased to be a Director on May 29, 2013. Mr. Huang was reappointed as an executive Director of our Company on November 27, 2014. Mr. Huang is also our vice president. He is in charge of the administrative management of our Group and the operations management of our subsidiaries and joint ventures. Mr. Huang joined Shenyang Sunshine in 1993 as a manager of the human resources department.

Mr. Huang received a diploma in Engineering from Northeast College of Engineering (東北工學院) (currently known as Northeast University (東北大學)) in July 1987. He attended a one-year training program in business management in Tsinghua University (清華大學) from April 2000 to April 2001.

Non-executive Directors

Mr. LIU Dong (劉東) was appointed as our non-executive Director on May 23, 2015. He is responsible for participating in the formulation of our Company’s corporate and business strategies. Mr. Liu has served as a director of Shenyang Sunshine since May 28, 2013.

Mr. Liu joined CITIC Private Equity Funds Management Co., Ltd (“CITIC PE”) in January 2009. He is a managing director of CITIC PE in charge of investment in the healthcare sector.

Mr. Liu also currently serves as a director of Zhejiang Beingmate Technology Industry & Trade Co. Ltd. (a company listed on the Shenzhen Stock Exchange with stock code 002570), Biosensors International Group, Ltd. (a company listed on the SGX-ST with symbol B20) and Luye Pharma Group Ltd. (a company listed on the Stock Exchange with stock code 2186).

Mr. Liu received a joint Bachelor’s degree in Physics and Finance from Nankai University (南開大學) in June 1995 and an Executive Master of Business Administration from China Europe International Business School (中歐國際工商學院) in October 2011.

Mr. WANG Steven Dasong was appointed as our non-executive Director on June 30, 2017.

Mr. Wang is a Managing Director and team leader for Pharmaceutical and Medtech Group at Citic PE, a multi-billion dollar China based PE firm. He has over 17 years of experience of working in top global investment banks and direct investment firms. Before joining Citic PE, Mr. Wang was a Managing Director and Head of APAC Healthcare Investment Banking at Credit Suisse. He previously held senior positions at investment banking department of UBS and Morgan Stanley in Hong Kong. He led a number of Asia healthcare and related deals including the IPO of Sinopharm Holdings, Luye Pharmaceutical and Rici Healthcare, the privatization of Wuxi Pharmatech and Simcere Pharmaceutical, as well as Luye’s acquisition of Acino and Sanofi-Aventis’ acquisition of BMP Sunstone. Before returning to China in 2007, Mr. Wang worked seven years in New York for multinational investment banks and multi-strategy hedge funds.

Before his career in finance, Steven Wang was a senior research scientist in the R&D department of Schering-Plough Corporation (now a part of Merck), focusing on allergy and immunology with multiple published paper and patents. Mr. Wang holds Ph.D. in Medicinal Chemistry from the Johns Hopkins University, and MBA in Finance (with distinction) from New York University. He is a Chartered Financial Analyst (CFA).

Independent Non-executive Directors

Mr. PU Tianruo (濮天若) was appointed as our independent non-executive Director on May 23, 2015 with such appointment taking effect on June 1, 2015. He is responsible for participating in decision-making and advising on issues relating to our Company’s significant events and corporate governance. Previously, he served as our independent Director, audit committee chair, special committee chair and compensation committee member from September 1, 2012 to May 29, 2013.

Mr. Pu has had substantial experience in corporate finance, accounting, mergers and acquisitions, as well as in the technology sector.

Mr. Pu obtained a Bachelor’s degree in English from China Foreign Affairs University (外交學院) in July 1991, a Master’s degree in Accounting from the University of Illinois, College of Business Administration in May 1996 and a Master of Business Administration from Northwestern University Kellogg School of Management in June 2000.

Dr. David Ross PARKINSON was appointed as our independent non-executive Director on May 23, 2015 with such appointment taking effect on June 1, 2015. He is responsible for participating in decision-making and advising on issues relating to our Company’s significant events and corporate governance.

From 2007 to 2012, Dr. Parkinson served as president and chief executive officer at Nodality, Inc., a biotechnology company focused on personalized medicine. Before that, he was a vice president and head of the clinical oncology therapeutic area at Amgen Inc. (a company listed on the NASDAQ with symbol AMGN).

Dr. Parkinson served as a director of the American Association for Cancer Research (AACR) from 2006 to 2009. He served on the National Cancer Policy Forum of the Institute of Medicine from 2005 to 2011.

Dr. Parkinson has received multiple awards and honors, including the top innovator award from the Multiple Myeloma Research Foundation in 2012 and the Wiley Medal from the USFDA in 1997. He delivered the 12th Andrew H. Weinberg Memorial Lecture at the Harvard University School of Medicine in 2008.

Dr. Parkinson obtained a Doctor of Medicine degree (M.D.) at the University of Toronto Faculty of Medicine in 1974.

Mr. MA Jun (馬駿) was appointed as our independent non-executive Director on May 23, 2015 with such appointment taking effect on June 1, 2015. He is responsible for participating in decision-making and advising on issues relating to our Company’s significant events and corporate governance. Mr. Ma has served as the chief executive officer of Rong & De (Tianjin) Investment Partnership (Limited Partnership) (熔安德(天律)投資合伙企業(有限合伙)) since April 2011 in charge of fund raising and management. Mr. Ma was an attorney of Commerce & Finance Law Offices from January 2006 to April 2007.

Mr. Ma obtained a Bachelor of Laws degree (L.L.B.) from Peking University (北京大學) in July 1985. He obtained a Juris Doctor degree (J.D.) from Cornell Law School in May 1996 and was subsequently admitted to the New York bar.

Corporate Governance Committees

Audit Committee

Terms of Reference of the Audit Committee

We have established an audit committee in compliance with Rule 3.21 of the Listing Rules and the Corporate Governance Code set out in Appendix 14 to the Listing Rules. The primary duties of the audit committee are to review and supervise the financial reporting process and internal controls system of the Group, review and approve connected transactions and to advise the Board. The audit committee comprises one non-executive Director, namely Mr. Lv Dong (呂東), and two independent non-executive Directors, namely Mr. Pu Tianruo (濮天若) and Mr. Ma Jun (馬駿). Mr. Pu Tianruo (濮天若), being the chairman of the committee, is appropriately qualified as required under Rules 3.10(2) and 3.21 of the Listing Rules.

Remuneration Committee

Terms of Reference of the Remuneration Committee

We have established a remuneration committee in compliance with Rule 3.25 of the Listing Rules and the Corporate Governance Code set out in Appendix 14 to the Listing Rules. The primary duties of the remuneration committee are to review and make recommendations to the Board regarding the terms of remuneration packages, bonuses and other compensation payable to our Directors and senior management. The remuneration committee comprises one non-executive Director namely, Mr. Liu Dong (劉東) and two independent non-executive Directors, namely Mr. Ma Jun (馬駿) and Mr. Pu Tianruo (濮天若), with Mr. Ma Jun (馬駿) being the chairman of the committee.

Nomination Committee

Terms of Reference of the Nomination Committee

We have established a nomination committee in compliance with the Code on Corporate Governance set out in Appendix 14 to the Listing Rules. The primary duties of the nomination committee are to make recommendations to our Board regarding the appointment of Directors and Board succession. The nomination committee comprises one executive Director namely, Mr. Lou Jing (婁競) and two independent non-executive Directors, namely Mr. Pu Tianruo (濮天若) and Mr. Ma Jun (馬駿), with Mr. Lou Jing (婁競) being the chairman of the committee.

Annual General Meeting

Director Nomination Procedure